Firstview Insight's Severe Psoriasis Pipeline Review2037 provides an overview of the pipeline landscape of Severe Psoriasis It provides comprehensive insights of all the clinical and nonclinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc.These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Psoriasis is a chronic debilitating disease in which dermatologists take a frontline role in improving the quality of life of affected patients. Although recent years have seen the advent of numerous new medications for the treatment of psoriasis, there still is considerable room for improvement in our treatment of this condition. Novel insights into the underlying mechanisms of psoriasis have yielded exciting new potential medications, many with promising preliminary efficacy data. The upcoming systemic agents for the treatment of psoriasis are presented in this article, encompassing novel biologics and smallmolecule medicines eg, IL17 receptor blockers, Janus kinase [Jak] inhibitors. The underlying mechanisms and currently available data for each drug will be discussed to impart a working knowledge of these new treatment options to dermatology residents, as these drugs may soon be added to our armamentarium for treating psoriasis.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and preclinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
The report provides a competitive landscape
The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and endpoint status
The report provides the list of companies which are the most active in the pipeline
The report covers pipeline products based on various stages of development ranging from preregistration till discovery
The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action MoA; route of administration RoA; Stage of development; clinical trial status; licensing and collaboration details other developmental activities
The report features comparative analysis of product profiles based on molecule type; mechanism of action MoA; route of administration RoA
The report summarizes all the dormant and discontinued pipeline projects
The report also provides latest news for the past one year
Reasons To Buy
To identifying prominent players in the treatment landscape
To determine the drivers; barriers and unmet need in the treatment space
Gain strategically significant competitor information; analysis; and insights to formulate effective RD strategies
Define inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
List of products
Enbrel
Humira
Cimzia
Cosentyx